Len Schleifer, Regeneron CEO (Andrew Harnik/AP Images)
With 7 PD-(L)1s on the market, price competition hasn't been a factor. Will Regeneron be the first to ask for less?
In what seems like a counterintuitive strategy, seven drugs have piled in the anti-PD-(L)1 market so far, all at roughly the same list price. With …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
